On the heels of a recent cost-cutting drive that severed much of AmplifyBio’s R&D capacity, the Ohio-based contract ...

While pharma giants Novo Nordisk and Eli Lilly may have a solid hold on the obesity arena, Rhythm Pharmaceuticals is looking ...

Art Garfunkel is breaking the sound of silence around his experience with plaque psoriasis. | Art Garfunkel is breaking the ...

| The right message served to the right patient sounds great, but even that pairing loses its power if it's served in the ...

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

Viatris has agreed to a settlement in which it will pay up to $335 million to resolve opioid-related claims to state and local governments, the Pittsburgh-based generics specialist said on Monday.

Massive cuts at the FDA have hit staff tied to drug reviews and user fees, putting future approvals in jeopardy, according to ...

With concerns mounting and speculation swirling, the particulars of President Donald Trump’s much-touted “Liberation Day” ...

With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth ...

Funnyman Kenan Thompson is opening up about the not-so-funny experience of living with gastroesophageal reflux disease (GERD) ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

As the FDA wavers from cuts, changes and departures under the second Trump administration, another vital figure of the agency ...